ET
Director, Clinical Development
Egetis Therapeutics AB
Remote · Europe, Middle East, and Africa
AS
arGenX SE is a global immunology company developing antibody-based treatments, such as VYVGART, for severe autoimmune diseases.
1 open job
Egetis Therapeutics AB
Specialty pharmaceutical company developing and commercialising treatments for rare diseases, led by Emcitate (tiratricol) for MCT8 deficiency.
Egetis Therapeutics AB is a specialty pharmaceutical company developing and commercialising treatments for rare diseases with high unmet medical need. Its lead product, Emcitate (tiratricol), is the first and only approved treatment for MCT8 deficiency in both the United States and the European Union. MCT8 deficiency is a rare, life-limiting disorder that disrupts thyroid hormone transport, resulting in severe neurodevelopmental impairment and systemic complications.
The company's work spans late-stage clinical development and pharmaceutical commercialisation, with particular focus on thyroid hormone transport disorders and neurodevelopmental conditions. To support expanding commercial operations, Egetis has established subsidiaries in the United States; its regulatory and market footprint covers the United States and the European Union, with a patient focus that is worldwide.
Egetis describes itself as an integrated pharmaceutical company with a mission-driven emphasis on serious conditions with high unmet medical need. It states a commitment to collaboration with the rare disease community and to making a meaningful difference for patients and families affected by these conditions.